Developments in Pharmacogenomics

Table of Contents

1. Executive Summary

• 1. Introduction
  • 1. Introduction to Pharmacogenomics
  • 2. Variable Drug Response and Adverse Reactions
  • 3. SNP Profiling
  • 4. FISH
  • 5. Companies Involved in Pharmacogenomics Research
• 2. Scope and Methodology
  • 1. Scope
  • 2. Methodology

2. Technology and Applications Viewpoint

• 1. Applications Analysis and Trends
  • 1. Primary Applications: Drug Discovery and Molecular Diagnostics
  • 2. Diagnosis Plus Therapy
  • 3. Personalized Medicine
• 2. Industry Trends and Assessments
  • 1. Market Factors
  • 2. Enabling Technologies and Their Markets

3. Innovative Developments in North America

• 1. Companies
  • 1. NitroMed: Genetic Variation Determines Response to Heart-Failure Drug
  • 2. Genecor: Second-Generation Interferon-Beta Molecule for Treatment of Multiple Sclerosis
  • 3. Monogram Biosciences: Cancer-Specific Dimers Determine Response to Chemotherapy
  • 4. Genizon BioSciences: Small Founder Population Allows Easier Linkage and SNP Mapping
  • 5. Nanogen: Improved Circuitry Increases Biochip Performance
  • 6. Affymetrix: CYP450 Test Approved in USA and Europe
  • 7. DNAPrint: Fewer SNPs Lower Genotyping Costs
  • 8. SimPheny: Computer Modeling for Predictions of Cellular Metabolism and Behavior
  • 9. Nanosphere: Gold Nanoparticles Allow Molecular Analysis without PCR
  • 10. Additional Companies-I
  • 11. Additional Companies-II
• 2. Academic and Government-Related Institutions
  • 1. Ohio State University: New Molecular Understanding to Tailor Treatments for Addiction
  • 2. Mayo Clinic: Protein Misfolding Leads Aggrosome to Disrupt Thiopurine Metabolism
  • 3. University of Florida: Researchers Identify Genes that Influence Response of Heart Failure Patients to Beta-Blockers
  • 4. University of Michigan: Herbal Therapy Potentiates Effect of Blood Thinner by Increasing CYP3A4 Activity
  • 5. Stanford University: Microarrays Predict Drug Response
  • 6. NIST: Fluorescent Quantum Dots Reduce FISH Uncertainty
  • 7. UCSF: E-Map Looks at Epistatic Interactions
  • 8. Harvard University: Automated Microscopy to Track Broad Effects of Drugs

4. Innovative Developments in Europe and Asia-Pacific

• 1. Companies
  • 1. Iceland: deCODE Genetics
  • 2. UK: Solexa
  • 3. Switzerland: Roche
  • 4. France: Serono Genetics Institute
  • 5. Germany: Epigenomics
  • 6. Netherlands: Qiagen N.V.
  • 7. India: Ocimum
  • 8. India: Avestha Gengraine
  • 9. India: Strand Genomics
• 2. Academic and Government-Related Institutions
  • 1. France: Magnetic Particles Speed DNA Separations on Chip
  • 2. Germany: Genetic Analysis without Labels
  • 3. Australia: CSIRO

5. Technology Adoption Factor Analysis

• 1. Development Restraints and Market Challenges
  • 1. Introduction
  • 2. Too Much Complexity
  • 3. Too Much Simplicity
  • 4. Too Much Optimism
  • 5. Clinical Trial Design
  • 6. Understanding Business Fundamentals
  • 7. Practicality of Point-of-Care
  • 8. Pharmaceutical Industry Reluctance
  • 9. Governmental Support--Financial and IP Protection
  • 10. Others
• 2. Adoption Drivers
  • 1. Drug Side Effects
  • 2. Pressure on Big Pharma to Accelerate Drug Discovery
  • 3. Need for Faster Identification of Failed Targets
  • 4. Identify Suitable Patient Population for Clinical Trials
  • 5. Demand for Personalized Medicine
  • 6. Others
• 3. Technology Features and Benefits
  • 1. Part I
  • 2. Part II
• 4. Analysis of Funding Sources
  • 1. European Government Funding for R&D
  • 2. USA: Pharmacogenetics Research Network
  • 3. Canadian Pharmacogenomic Funding

6. Database of Key Industry Participants and Selected Patents

• 1. Key Industry Participants
  • 1. North America
  • 2. Europe and Asia Pacific
• 2. Patents
  • 1. Patents--I
  • 2. Patents--II
  • 3. Patents--III

7. Frost & Sullivan 2005 Science & Technology Awards

• 1. Excellence in Technology Award
  • 1. Award Description
  • 2. Award Recipient
• 2. Technology Innovation Award
  • 1. Award Description
  • 2. Award Recipient
• 3. Technology Leadership Award
  • 1. Award Description
  • 2. Award Recipient

8. Critical Reference Tables

• 1. Healthcare and Pharma R&D Expenditure
  • 1. Total Healthcare Expenditure (1999-2006)
  • 2. Pharma R&D Expenditure (1999-2006)
• 2. Biotechnology R&D Expenditure
  • 1. Number of Biotechnology Companies (1999-2006)
  • 2. Government Investment in Biotechnology R&D (1999-2006)
  • 3. Private Investment in Biotechnology R&D (1999-2006)